PALO ALTO, Calif., March 16, 2020 /PRNewswire/ — Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2019. “We made tremendous progress this past year toward our goal of developing a next … Continued

PALO ALTO, Calif., Feb. 27, 2020 /PRNewswire/ — Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, announced today that management will present at the following upcoming investor conferences: Cowen 40th Annual Health Care Conference in Boston, MA on Wednesday, March 4 at 10:00 … Continued

Encouraging safety profile continues with zero cases of intraocular inflammation after 420 doses in 130 patients Strong anti-VEGF efficacy with extended dosing intervals continues to be observed across all three of the major retinal vascular diseases Promising clinical durability continues to be observed with 84% of wet AMD treated eyes and 76% of DME treated … Continued

PALO ALTO, Calif., Feb. 5, 2020 /PRNewswire/ — Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, announced today that a presentation of additional clinical study data on its investigational therapy KSI-301 will be made at the Angiogenesis, Exudation, and Degeneration 2020 meeting being held on February 8, 2020, … Continued

PALO ALTO, Calif., Dec. 19, 2019 /PRNewswire/ — Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced the appointment of Taiyin Yang, Ph.D., to its board of directors. Currently, Dr. Yang serves as Executive Vice President, Pharmaceutical Development and Manufacturing at Gilead Sciences, Inc. “Dr. Yang joins our board in a … Continued

PALO ALTO, Calif., Dec. 6, 2019 /PRNewswire/ — Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced the closing of its previously announced underwritten public offering of 6,900,000 shares of its common stock, which includes 900,000 shares sold pursuant to the underwriters’ exercise in full of … Continued

PALO ALTO, Calif., Dec. 3, 2019 /PRNewswire/ — Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced the pricing of an underwritten public offering of 6,000,000 shares of its common stock at a price to the public of $46.00 per share. The aggregate gross proceeds from the offering are … Continued

PALO ALTO, Calif., Dec. 2, 2019 /PRNewswire/ — Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that it has commenced an underwritten public offering of $250,000,000 of shares of its common stock. In connection with the proposed offering, Kodiak Sciences expects … Continued

– Kodiak Sells Capped Royalty Right on Global Net Sales of KSI-301 for $225 million– Royalty Rate of 4.5% on Annual Net Sales Terminates after 4.5 times the Funded Amount Has Been Paid– Transaction Enables an Immediate Acceleration of Clinical, Manufacturing and Commercial Investments Towards Kodiak’s “2022 Vision” PALO ALTO, Calif., Dec. 2, 2019 /PRNewswire/ — Kodiak Sciences … Continued

PALO ALTO, Calif., Nov. 12, 2019 /PRNewswire/ — Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today reported business highlights and financial results for the third quarter ended September 30, 2019. “During the third quarter and into the early fourth quarter, we presented promising safety, efficacy, and durability … Continued